Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELASTIC: Roflumilast effects on atherosclerosis in stable COPD
NCT01630200Phase 4Completed
- Sponsor
- Ludwig Boltzmann Institute for COPD and Respiratory Epidemiology
- Start
- May 2012
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Roflumilast with Placebo (2 arms). Primary endpoint: Carotid Femoral-Pulse Wave Velocity at 6 months. Started May 2012; status: completed.
02
Drugs
roflumilast
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01630200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01630200.